nach oben

Current Diabetes Reports

Erschienen in:

01.07.2020 | Immunology, Transplantation, and Regenerative Medicine (L Piemonti and V Sordi, Section Editors)

Updates on Gene Therapy for Diabetic Retinopathy

verfasst von: Jiang-Hui Wang, Georgina Eloise Roberts, Guei-Sheung Liu

Erschienen in: Current Diabetes Reports | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Diabetic retinopathy (DR), a leading cause of visual impairment in the developed country, is characterized by vascular lesions and neuronal damage of the retina. Treatment options for this condition are currently limited. The advent of therapy targeting vascular endothelial growth factor (VEGF) demonstrated significant benefits to patients with DR. However, this treatment is limited by its short half-life and requirement for frequent invasive intravitreal injections. In addition, many patients failed to achieve clinically significant improvement in visual function. Gene therapy has the potential to provide an alternative treatment for DR with distinct advantages, such as longer therapeutic effect, less injection frequency, ability to intervene at disease onset, and potentially fewer side effects.

Recent Findings

Strategies for gene therapy in DR, stemming from the current understanding of the disease pathogenesis, focus on the inhibition of neovascularization and protection of neurovascular degeneration in the retina. Studies with promising results have mainly focussed on animal models due to efficacy and safety concerns, despite a number of successful preclinical studies using adeno-associated virus-mediated transduction to treat both vascular dysfunction and neuronal degeneration. With the optimization of delivery vectors, transgene regulation, and outcome measure, gene therapy will potentially become available for patients with DR.

Summary

This review provides an update on the current strategies utilized in DR gene therapy research. Several barriers to the clinical application of gene therapy for DR are highlighted, and future directions for this research are proposed.

Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science. 1995;270(5235):475–80. https://doi.org/10.1126/science.270.5235.475.CrossRefPubMed

Yla-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther. 2012;20(10):1831–2. https://doi.org/10.1038/mt.2012.194.CrossRefPubMedPubMedCentral

Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F. Rationally engineered Cas9 nucleases with improved specificity. Science. 2016;351(6268):84–8. https://doi.org/10.1126/science.aad5227.CrossRefPubMed

Smalley E. First AAV gene therapy poised for landmark approval. Nat Biotechnol. 2017;35(11):998–9. https://doi.org/10.1038/nbt1117-998.CrossRefPubMed

Wong TY, Cheung CM, Larsen M, Sharma S, Simo R. Diabetic retinopathy. Nat Rev Dis Primers. 2016;2:16012. https://doi.org/10.1038/nrdp.2016.12.CrossRefPubMed

Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–64. https://doi.org/10.2337/dc11-1909.CrossRefPubMedPubMedCentral

Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50. https://doi.org/10.1016/j.diabres.2017.03.024.CrossRefPubMed

Wang JH, Ling D, Tu L, van Wijngaarden P, Dusting GJ, Liu GS. Gene therapy for diabetic retinopathy: are we ready to make the leap from bench to bedside? Pharmacol Ther. 2017;173:1–18. https://doi.org/10.1016/j.pharmthera.2017.01.003.CrossRefPubMed

Abcouwer SF, Gardner TW. Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment. Ann N Y Acad Sci. 2014;1311:174–90. https://doi.org/10.1111/nyas.12412.CrossRefPubMedPubMedCentral

10.

Simo R, Hernandez C. European Consortium for the Early Treatment of Diabetic R. Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab. 2014;25(1):23–33. https://doi.org/10.1016/j.tem.2013.09.005.CrossRefPubMed

11.

Simo R, Hernandez C. Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence. Prog Retin Eye Res. 2015;48:160–80. https://doi.org/10.1016/j.preteyeres.2015.04.003.CrossRefPubMed

12.

Barber AJ, Gardner TW, Abcouwer SF. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2011;52(2):1156–63. https://doi.org/10.1167/iovs.10-6293.CrossRefPubMedPubMedCentral

13.

Du Y, Veenstra A, Palczewski K, Kern TS. Photoreceptor cells are major contributors to diabetes-induced oxidative stress and local inflammation in the retina. Proc Natl Acad Sci U S A. 2013;110(41):16586–91. https://doi.org/10.1073/pnas.1314575110.CrossRefPubMedPubMedCentral

14.

Lee JH, Wang JH, Chen J, Li F, Edwards TL, Hewitt AW, et al. Gene therapy for visual loss: opportunities and concerns. Prog Retin Eye Res. 2019;68:31–53. https://doi.org/10.1016/j.preteyeres.2018.08.003.CrossRefPubMed

15.

Sun P, Liu Z. Overexpressing kringle 1 domain of hepatocyte growth factor with adeno-associated virus inhibits the pathological retinal neovascularization in an oxygen-induced retinopathy mouse model. Biochem Biophys Res Commun. 2019;508(1):130–7. https://doi.org/10.1016/j.bbrc.2018.11.111.CrossRefPubMed

16.

Tu L, Wang JH, Barathi VA, Prea SM, He Z, Lee JH, et al. AAV-mediated gene delivery of the calreticulin anti-angiogenic domain inhibits ocular neovascularization. Angiogenesis. 2018;21(1):95–109. https://doi.org/10.1007/s10456-017-9591-4.CrossRefPubMed

17.

Biswal MR, Prentice HM, Dorey CK, Blanks JC. A hypoxia-responsive glial cell-specific gene therapy vector for targeting retinal neovascularization. Invest Ophthalmol Vis Sci. 2014;55(12):8044–53. https://doi.org/10.1167/iovs.14-13932.CrossRefPubMedPubMedCentral

18.

Haurigot V, Villacampa P, Ribera A, Bosch A, Ramos D, Ruberte J, et al. Long-term retinal PEDF overexpression prevents neovascularization in a murine adult model of retinopathy. PLoS One. 2012;7(7):e41511. https://doi.org/10.1371/journal.pone.0041511.CrossRefPubMedPubMedCentral

19.

Pechan P, Rubin H, Lukason M, Ardinger J, DuFresne E, Hauswirth WW, et al. Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther. 2009;16(1):10–6. https://doi.org/10.1038/gt.2008.115.CrossRefPubMed

20.

Lai CM, Shen WY, Brankov M, Lai YK, Barnett NL, Lee SY, et al. Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol Ther. 2005;12(4):659–68.

21.

Jiang J, Xia XB, Xu HZ, Xiong Y, Song WT, Xiong SQ, et al. Inhibition of retinal neovascularization by gene transfer of small interfering RNA targeting HIF-1alpha and VEGF. J Cell Physiol. 2009;218(1):66–74. https://doi.org/10.1002/jcp.21566.CrossRefPubMed

22.

Lamartina S, Cimino M, Roscilli G, Dammassa E, Lazzaro D, Rota R, et al. Helper-dependent adenovirus for the gene therapy of proliferative retinopathies: stable gene transfer, regulated gene expression and therapeutic efficacy. J Gene Med. 2007;9(10):862–74. https://doi.org/10.1002/jgm.1083.CrossRefPubMed

23.

Ideno J, Mizukami H, Kakehashi A, Saito Y, Okada T, Urabe M, et al. Prevention of diabetic retinopathy by intraocular soluble flt-1 gene transfer in a spontaneously diabetic rat model. Int J Mol Med. 2007;19(1):75–9.PubMed

24.

Le Gat L, Gogat K, Bouquet C, Saint-Geniez M, Darland D, Van Den Berghe L, et al. In vivo adenovirus-mediated delivery of a uPA/uPAR antagonist reduces retinal neovascularization in a mouse model of retinopathy. Gene Ther. 2003;10(25):2098–103. https://doi.org/10.1038/sj.gt.3302122.CrossRefPubMed

25.

Igarashi T, Miyake K, Kato K, Watanabe A, Ishizaki M, Ohara K, et al. Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model. Gene Ther. 2003;10(3):219–26. https://doi.org/10.1038/sj.gt.3301878.CrossRefPubMed

26.

Gehlbach P, Demetriades AM, Yamamoto S, Deering T, Xiao WH, Duh EJ, et al. Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. Hum Gene Ther. 2003;14(2):129–41. https://doi.org/10.1089/104303403321070829.CrossRefPubMed

27.

Auricchio A, Behling KC, Maguire AM, O'Connor EM, Bennett J, Wilson JM, et al. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol Ther. 2002;6(4):490–4. https://doi.org/10.1006/mthe.2002.0702.CrossRefPubMed

28.

Bainbridge JW, Mistry A, De Alwis M, Paleolog E, Baker A, Thrasher AJ, et al. Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther. 2002;9(5):320–6. https://doi.org/10.1038/sj.gt.3301680.CrossRefPubMed

29.

Prea SM, Chan EC, Dusting GJ, Vingrys AJ, Bui BV, Liu GS. Gene therapy with endogenous inhibitors of angiogenesis for neovascular age-related macular degeneration: beyond anti-VEGF therapy. J Ophthalmol. 2015;2015:201726–12. https://doi.org/10.1155/2015/201726.CrossRefPubMedPubMedCentral

30.

Lai YK, Shen WY, Brankov M, Lai CM, Constable IJ, Rakoczy PE. Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther. 2002;9(12):804–13. https://doi.org/10.1038/sj.gt.3301695.CrossRefPubMed

31.

Zhang X, Das SK, Passi SF, Uehara H, Bohner A, Chen M, et al. AAV2 delivery of Flt23k intraceptors inhibits murine choroidal neovascularization. Mol Ther. 2015;23(2):226–34. https://doi.org/10.1038/mt.2014.199.CrossRefPubMed

32.

O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79(2):315–28. https://doi.org/10.1016/0092-8674(94)90200-3.CrossRefPubMed

33.

O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277–85. https://doi.org/10.1016/s0092-8674(00)81848-6.CrossRefPubMed

34.

Zhang M, Yang Y, Yan M, Zhang J. Downregulation of vascular endothelial growth factor and integrinbeta3 by endostatin in a mouse model of retinal neovascularization. Exp Eye Res. 2006;82(1):74–80. https://doi.org/10.1016/j.exer.2005.05.005.CrossRefPubMed

35.

Kim KS, Hong YK, Lee Y, Shin JY, Chang SI, Chung SI, et al. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain. Exp Mol Med. 2003;35(6):578–85. https://doi.org/10.1038/emm.2003.76.CrossRefPubMed

36.

Xin L, Xu R, Zhang Q, Li TP, Gan RB. Kringle 1 of human hepatocyte growth factor inhibits bovine aortic endothelial cell proliferation stimulated by basic fibroblast growth factor and causes cell apoptosis. Biochem Biophys Res Commun. 2000;277(1):186–90. https://doi.org/10.1006/bbrc.2000.3658.CrossRefPubMed

37.

Sun Z, Zhang PX, Wang P, Gurewich V, Shen HY, Liu JN. Amino-terminal fragment of urokinase-type plasminogen activator inhibits its plasminogen activation. Thromb Res. 2002;106(2):105–11. https://doi.org/10.1016/s0049-3848(02)00091-9.CrossRefPubMed

38.

Shen Z, Yang ZF, Gao Y, Li JC, Chen HX, Liu CC, et al. The kringle 1 domain of hepatocyte growth factor has antiangiogenic and antitumor cell effects on hepatocellular carcinoma. Cancer Res. 2008;68(2):404–14. https://doi.org/10.1158/0008-5472.CAN-07-2081.CrossRefPubMed

39.

Diaz-Lezama N, Wu Z, Adan-Castro E, Arnold E, Vazquez-Membrillo M, Arredondo-Zamarripa D, et al. Diabetes enhances the efficacy of AAV2 vectors in the retina: therapeutic effect of AAV2 encoding vasoinhibin and soluble VEGF receptor 1. Lab Investig. 2016;96(3):283–95. https://doi.org/10.1038/labinvest.2015.135.CrossRefPubMed

40.

Ramirez M, Wu Z, Moreno-Carranza B, Jeziorski MC, Arnold E, Diaz-Lezama N, et al. Vasoinhibin gene transfer by adenoassociated virus type 2 protects against VEGF- and diabetes-induced retinal vasopermeability. Invest Ophthalmol Vis Sci. 2011;52(12):8944–50. https://doi.org/10.1167/iovs.11-8190.CrossRefPubMed

41.

Ao H, Liu B, Li H, Lu L. Egr1 mediates retinal vascular dysfunction in diabetes mellitus via promoting p53 transcription. J Cell Mol Med. 2019;23(5):3345–56. https://doi.org/10.1111/jcmm.14225.CrossRefPubMedPubMedCentral

42.

Mao XB, Cheng YH, Xu YY. miR-204-5p promotes diabetic retinopathy development via downregulation of microtubule-associated protein 1 light chain 3. Exp Ther Med. 2019;17(4):2945–52. https://doi.org/10.3892/etm.2019.7327.CrossRefPubMedPubMedCentral

43.

Dominguez JM 2nd, Hu P, Caballero S, Moldovan L, Verma A, Oudit GY, et al. Adeno-associated virus overexpression of angiotensin-converting Enzyme-2 reverses diabetic retinopathy in type 1 diabetes in mice. Am J Pathol. 2016;186(6):1688–700. https://doi.org/10.1016/j.ajpath.2016.01.023.CrossRefPubMedPubMedCentral

44.

Zhang L, Xia H, Han Q, Chen B. Effects of antioxidant gene therapy on the development of diabetic retinopathy and the metabolic memory phenomenon. Graefes Arch Clin Exp Ophthalmol. 2015;253(2):249–59. https://doi.org/10.1007/s00417-014-2827-8.CrossRefPubMed

45.

Xu H, Zhang L, Gu L, Lu L, Gao G, Li W, et al. Subretinal delivery of AAV2-mediated human erythropoietin gene is protective and safe in experimental diabetic retinopathy. Invest Ophthalmol Vis Sci. 2014;55(3):1519–30. https://doi.org/10.1167/iovs.13-13155.CrossRefPubMed

46.

Adhi M, Cashman SM, Kumar-Singh R. Adeno-associated virus mediated delivery of a non-membrane targeted human soluble CD59 attenuates some aspects of diabetic retinopathy in mice. PLoS One. 2013;8(10):e79661. https://doi.org/10.1371/journal.pone.0079661.CrossRefPubMedPubMedCentral

47.

Verma A, Shan Z, Lei B, Yuan L, Liu X, Nakagawa T, et al. ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy. Mol Ther. 2012;20(1):28–36. https://doi.org/10.1038/mt.2011.155.CrossRefPubMed

48.

Gong Y, Chang ZP, Ren RT, Wei SH, Zhou HF, Chen XF, et al. Protective effects of adeno-associated virus mediated brain-derived neurotrophic factor expression on retinal ganglion cells in diabetic rats. Cell Mol Neurobiol. 2012;32(3):467–75. https://doi.org/10.1007/s10571-011-9779-x.CrossRefPubMed

49.

Gao N, Wang H, Yin H, Yang Z. Angiotensin II induces calcium-mediated autophagy in podocytes through enhancing reactive oxygen species levels. Chem Biol Interact. 2017;277:110–8. https://doi.org/10.1016/j.cbi.2017.09.010.CrossRefPubMed

50.

Alizadeh S, Mazloom H, Sadeghi A, Emamgholipour S, Golestani A, Noorbakhsh F, et al. Evidence for the link between defective autophagy and inflammation in peripheral blood mononuclear cells of type 2 diabetic patients. J Physiol Biochem. 2018;74(3):369–79. https://doi.org/10.1007/s13105-018-0624-2.CrossRefPubMed

51.

Ghosh P, Sahoo R, Vaidya A, Chorev M, Halperin JA. Role of complement and complement regulatory proteins in the complications of diabetes. Endocr Rev. 2015;36(3):272–88. https://doi.org/10.1210/er.2014-1099.CrossRefPubMedPubMedCentral

52.

Mitsuhashi J, Morikawa S, Shimizu K, Ezaki T, Yasuda Y, Hori S. Intravitreal injection of erythropoietin protects against retinal vascular regression at the early stage of diabetic retinopathy in streptozotocin-induced diabetic rats. Exp Eye Res. 2013;106:64–73. https://doi.org/10.1016/j.exer.2012.11.001.CrossRefPubMed

53.

Calderon GD, Juarez OH, Hernandez GE, Punzo SM, De la Cruz ZD. Oxidative stress and diabetic retinopathy: development and treatment. Eye (Lond). 2017;31(8):1122–30. https://doi.org/10.1038/eye.2017.64.CrossRef

54.

Renna NF, Lembo C, Diez E, Miatello RM. Role of renin-angiotensin system and oxidative stress on vascular inflammation in insulin resistence model. Int J Hypertens. 2013;2013:420979. https://doi.org/10.1155/2013/420979.CrossRefPubMedPubMedCentral

55.

Ferreira AJ, Santos RA, Bradford CN, Mecca AP, Sumners C, Katovich MJ, et al. Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension. 2010;55(2):207–13. https://doi.org/10.1161/HYPERTENSIONAHA.109.140145.CrossRefPubMed

56.

Huang X, Zhou G, Wu W, Duan Y, Ma G, Song J, et al. Genome editing abrogates angiogenesis in vivo. Nat Commun. 2017;8(1):112. https://doi.org/10.1038/s41467-017-00140-3.CrossRefPubMedPubMedCentral

57.

Koo T, Park SW, Jo DH, Kim D, Kim JH, Cho HY, et al. CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of age-related macular degeneration. Nat Commun. 2018;9(1):1855. https://doi.org/10.1038/s41467-018-04175-y.CrossRefPubMedPubMedCentral

58.

Adli M. The CRISPR tool kit for genome editing and beyond. Nat Commun. 2018;9(1):1911. https://doi.org/10.1038/s41467-018-04252-2.CrossRefPubMedPubMedCentral

59.

Ciulla TA, Rosenfeld PJ. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration. Curr Opin Ophthalmol. 2009;20(3):166–74. https://doi.org/10.1097/ICU.0b013e328329d173.CrossRefPubMed

60.

Garba AO, Mousa SA. Bevasiranib for the treatment of wet, age-related macular degeneration. Ophthalmol Eye Dis. 2010;2:75–83. https://doi.org/10.4137/OED.S4878.CrossRefPubMedPubMedCentral

61.

Fedorov Y, Anderson EM, Birmingham A, Reynolds A, Karpilow J, Robinson K, et al. Off-target effects by siRNA can induce toxic phenotype. RNA. 2006;12(7):1188–96. https://doi.org/10.1261/rna.28106.CrossRefPubMedPubMedCentral

62.

Rakoczy EP. Gene therapy for the long term treatment of wet AMD. Lancet. 2017;390(10089):6–7. https://doi.org/10.1016/S0140-6736(17)31262-X.CrossRefPubMed

63.

FDA approves hereditary blindness gene therapy. Nat Biotechnol. 2018;36(1):6. https://doi.org/10.1038/nbt0118-6a.

64.

Miller JW, Vandenberghe LH. Breaking and sealing barriers in retinal gene therapy. Mol Ther. 2018;26(9):2081–2. https://doi.org/10.1016/j.ymthe.2018.08.003.CrossRefPubMedPubMedCentral

65.

Dalkara D, Byrne LC, Klimczak RR, Visel M, Yin L, Merigan WH, et al. In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med. 2013;5(189):189ra76. https://doi.org/10.1126/scitranslmed.3005708.CrossRefPubMed

66.

Zinn E, Pacouret S, Khaychuk V, Turunen HT, Carvalho LS, Andres-Mateos E, et al. In Silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector. Cell Rep. 2015;12(6):1056–68. https://doi.org/10.1016/j.celrep.2015.07.019.CrossRefPubMedPubMedCentral

67.

McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 2001;8(16):1248–54. https://doi.org/10.1038/sj.gt.3301514.CrossRefPubMed

68.

Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15(8):541–55. https://doi.org/10.1038/nrg3763.CrossRefPubMed

69.

Quintino L, Namislo A, Davidsson M, Breger LS, Kavanagh P, Avallone M, et al. Destabilizing domains enable long-term and inert regulation of GDNF expression in the brain. Mol Ther Methods Clin Dev. 2018;11:29–39. https://doi.org/10.1016/j.omtm.2018.08.008.CrossRefPubMedPubMedCentral

70.

Datta S, Renwick M, Chau VQ, Zhang F, Nettesheim ER, Lipinski DM, et al. A destabilizing domain allows for fast, noninvasive, conditional control of protein abundance in the mouse eye - implications for ocular gene therapy. Invest Ophthalmol Vis Sci. 2018;59(12):4909–20. https://doi.org/10.1167/iovs.18-24987.CrossRefPubMedPubMedCentral

71.

Breger L, Wettergren EE, Quintino L, Lundberg C. Regulated gene therapy. Methods Mol Biol. 2016;1382:57–66. https://doi.org/10.1007/978-1-4939-3271-9_4.CrossRefPubMed

72.

Prentice HM, Biswal MR, Dorey CK, Blanks JC. Hypoxia-regulated retinal glial cell-specific promoter for potential gene therapy in disease. Invest Ophthalmol Vis Sci. 2011;52(12):8562–70. https://doi.org/10.1167/iovs.10-6835.CrossRefPubMedPubMedCentral

73.

Geisler A, Fechner H. MicroRNA-regulated viral vectors for gene therapy. World J Exp Med. 2016;6(2):37–54. https://doi.org/10.5493/wjem.v6.i2.37.CrossRefPubMedPubMedCentral

74.

Thompson DA, Ali RR, Banin E, Branham KE, Flannery JG, Gamm DM, et al. Advancing therapeutic strategies for inherited retinal degeneration: recommendations from the Monaciano Symposium. Invest Ophthalmol Vis Sci. 2015;56(2):918–31. https://doi.org/10.1167/iovs.14-16049.CrossRefPubMedPubMedCentral

75.

Kiser AK, Mladenovich D, Eshraghi F, Bourdeau D, Dagnelie G. Reliability and consistency of visual acuity and contrast sensitivity measures in advanced eye disease. Optom Vis Sci. 2005;82(11):946–54. https://doi.org/10.1097/01.opx.0000187863.12609.7b.CrossRefPubMed

76.

Nair P, Aiello LP, Gardner TW, Jampol LM, Ferris FL III. Report from the NEI/FDA diabetic retinopathy clinical trial design and endpoints workshop. Invest Ophthalmol Vis Sci. 2016;57(13):5127–42. https://doi.org/10.1167/iovs.16-20356.CrossRefPubMedPubMedCentral

77.

Ip MS, Zhang J, Ehrlich JS. The clinical importance of changes in diabetic retinopathy severity score. Ophthalmology. 2017;124(5):596–603. https://doi.org/10.1016/j.ophtha.2017.01.003.CrossRefPubMed

Titel: Updates on Gene Therapy for Diabetic Retinopathy
verfasst von: Jiang-Hui Wang
Georgina Eloise Roberts
Guei-Sheung Liu
Publikationsdatum: 01.07.2020
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 7/2020
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-020-01308-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2020

Correction to: “H” for Heterogeneity in the Algorithm for Type 2 Diabetes Management

Euglycemic Ketoacidosis

Managing Diabetes in Hard to Reach Populations: A Review of Telehealth Interventions

Economic Simulation Modeling in Type 2 Diabetes

Using Person-Reported Outcomes (PROs) to Motivate Young People with Diabetes